Traditional Chinese Medicine: In the medium and long term, it is recommended to focus on two main lines, and in the short term, focus on the targets with good performance in the interim report

[Pharmaceutical Network Market Analysis] In recent years, a series of favorable policies have been introduced, which has greatly promoted the development of the traditional Chinese medicine indust.
For investment in the traditional Chinese medicine industry, analysts said that they should pay attention to the performance of the interim report in the short term, and it is recommended to pay attention to the targets with better performance in the interim repo.
According to statistics, as of now, 18 Chinese medicine listed companies have released performance forecasts, of which 9 companies have achieved positive year-on-year growth in net profit, and 8 companies have achieved a year-on-year growth rate of more than 50% in net prof.
For example, in the first half of the year, Dong'e Ejiao is expected to achieve a year-on-year increase of 80%-127% in net profit, about 270 million-340 million yu.
Taiji Group expects that the net profit attributable to shareholders of listed companies in the first half of 2022 will increase by 56% year-on-year to approximately RMB 120 million; the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses will increase by 102% year-on-year to approximately RMB 170 milli.
Jiuzhitang expects that the net profit attributable to shareholders of listed companies in the first half of 2022 will increase by 383%-587% year-on-year, approximately 307 million yuan to 351 million yu.
Regarding the pre-increase in performance, Dong'e Ejiao said that it will closely follow the main strategic line centered on consumer demand, continuously optimize product structure, and upgrade product mix; Achieve customer growth and performance improveme.
Taiji Group said that it focused on the development of its main business, implemented the strategy of main products, increased the sales of large-scale and large varieties, and drove the sales growth of other produc.
At the same time, it strictly controlled costs, improved quality and efficiency, and achieved sales revenue and gross prof.
substantial grow.
In the medium and long term, analysts believe that "policy + rigidity in pharmaceutical consumption + steady growth in performance + valuation advantages" jointly build investment opportunities in the traditional Chinese medicine indust.
It is recommended to focus on two main lin.
Main line 1: Inheritance and innovation line, pay attention to the innovation of traditional Chinese medicine, brand traditional Chinese medicine and traditional Chinese medicine formula granul.
Taking GPHL as an example, its high starting point plan aims at the core key of the development of the traditional Chinese medicine industry, "stuck neck" technology and products, through innovative traditional Chinese medicine research and development, secondary development of famous Chinese patent medicines, and international standardization innovation of traditional Chinese medicine, to become bigger and strong.
Traditional Chinese medicine products, continue to play the role of the industry to drive the high-quality development of the indust.
According to the current information disclosed this year, Yunnan Baiyao has a strategy to further enter the research and development of innovative traditional Chinese medicin.
For example, on March 3, Yunnan Baiyao issued an announcement that the clinical trial of Quansanqi Tablets, a class 1 innovative drug of traditional Chinese medicine, was approved by the State Drug Administrati.
Analysts pointed out that the policy support for the traditional Chinese medicine industry covers the entire industrial chain of traditional Chinese medicine, involving upstream Chinese herbal medicine planting, traditional Chinese medicine service system, talent construction, inheritance and innovation, open development, medical insurance payment, review and approval, e.
The industry has ushered in a policy dividend peri.
Chinese medicine innovation, brand Chinese medicine and Chinese medicine formula granules are the segments that benefit relatively mo.
Main line 2: Policy safe haven line, focusing on partial consumption and OTC terminal expansi.
The centralized procurement of Chinese patent medicines was relatively moderate, and the exclusive varieties performed bett.
In the context of centralized procurement, the expansion of OTC terminals can help traditional Chinese medicine companies to smooth out the impact of price reductions brought about by centralized procurement at the hospit.
It is understood that in recent years, various departments have promoted the innovation of the traditional Chinese medicine industry through continuous reform and optimization of traditional Chinese medicine regulatory policies, systems and measures, and the scale and level of China's traditional Chinese medicine industry have been significantly improv.
According to the data, in 2021, the operating income of Chinese herbal decoction pieces will reach 206 billion yuan, a year-on-year increase of 17%, and the profit will increase by 104%; the operating income of Chinese patent medicine will reach 482 billion yuan, a year-on-year increase of 19%, and the profit will increase by 2
Analysts pointed out that since last year, favorable policies for the traditional Chinese medicine industry have been gradually implemented, medical insurance payment has been tilted towards traditional Chinese medicine, and the industry policy margin has improv.
The market is worth looking forward .
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.